Martin T. Meehan, a former U.S. congressman who became chancellor of his alma mater, UMass Lowell, and transformed it into a highly ranked national research university, was unanimously elected today as the next president of the five-campus UMass system.
Michael R. Green, MD, PhD, has been appointed director of the UMass Medical School Cancer Center, Terence R. Flotte, MD, executive deputy chancellor, provost and dean of the school of medicine, has announced.
The Massachusetts Life Sciences Center announced a $5 million grant to UMass Medical School for the purchase of a high resolution cryo-electron microscope, bringing this breakthrough imaging technology to a campus poised to usher in the next generation of drug design and discovery.
Scientists in the lab of Marian Walhout, PhD, have applied a powerful tool in a new way to characterize genetic variants associated with human disease that will allow researchers to more easily and efficiently describe genomic variations underlying complex, multi-gene diseases.
In a promising breakthrough for smokers who are trying to quit, neuroscientists at UMass Medical School and The Scripps Research Institute have identified novel circuitry in the brain responsible for anxiety commonly experienced during withdrawal from nicotine addiction.
Six runners will take on the famous 26.1-mile Boston Marathon stretch from Hopkinton to Boston on April 20 to raise money for the UMass ALS Cellucci Fund.
An advanced smartphone application developed at Worcester Polytechnic Institute to help people with diabetes better manage their weight and blood sugar level and assess the status of chronic foot ulcers, is entering a pilot clinical study at UMass Medical School.
UMass Medical School researchers are using CRISPR/Cas9, a powerful gene editing tool, to develop a novel technology that can potentially cut the DNA of the latent HIV virus out of an infected cell.
Vanni Bucci, PhD, from UMass Dartmouth, is collaborating with colleagues in the UMass Center for Microbiome Research to sequence the intestinal microbiome with the goal of targeting treatments for specific enteric diseases and prototyping probiotic cocktails that could be used as a substitute for antibiotic treatment.
Fecal transplant, a novel therapy that Randy Pellish, MD, is exploring with his patients who have recurrent C. diff, is proving to be more than 90 percent effective.